Twelve this month.
Enjoy!
Ries R, Krupski A, West
II, Maynard C, Bumgardner K, Donovan D, Dunn C, Roy-Byrne P.
J Addict Med. 2015
Oct;9(5):417-26. doi: 10.1097/ADM.0000000000000151.
Comment: Can’t
access the full article, but the abstract suggests a fascinating look into
opioid-using safety net primary care patients.
Kazour F, Soufia M,
Rohayem J, Richa S.
Community Ment Health J.
2015 Sep 30. [Epub ahead of print]
Comment: Most
studies of heroin users find that heroin is *not* the usual method of suicide
attempts. Interestingly, this study finds something quite different, with
nearly half of attempts being through heroin use in Lebanon.
Roxburgh A, Hall WD,
Burns L, Pilgrim J, Saar E, Nielsen S, Degenhardt L.
Med J Aust. 2015 Oct
5;203(7):299.
Comment: Interesting
paper exploring deaths related to one, low-potency, opioid. Those deaths seemed
to be increasing, over a third were intentional (that’s much higher than other
opioids), and a remarkably high proportion were polydrug – which makes sense
since it would be tough to die from codeine alone.
Kampman K, Jarvis M.
J Addict Med. 2015
Oct;9(5):358-67. doi: 10.1097/ADM.0000000000000166.
Comment: Another
that I can’t access but whose abstract looks compelling.
Kharasch ED, Regina KJ,
Blood J, Friedel C.
Anesthesiology. 2015 Sep
19. [Epub ahead of print]
Comment: Ah,
the complexities of methadone. Genetic differences in hepatic metabolism are
more prominent in oral than intravenous methadone.
Kimber J, Larney S,
Hickman M, Randall D, Degenhardt L.
Lancet Psychiatry. 2015
Sep 15. pii: S2215-0366(15)00366-1. doi: 10.1016/S2215-0366(15)00366-1. [Epub
ahead of print]
Comment: There
is likely a mortality benefit to buprenorphine in the initiation of treatment,
but after that methadone and buprenorphine are comparable. I’ll admit that I’m
a bit surprised by that – I would have expected an ongoing relative benefit to
buprenorphine (there was a possible benefit to buprenorphine in all-cause
mortality during the treatment time). Of note for treatment programs, even if
the eventual treatment is methadone, it may be possible to avert the initiation
mortality risk by starting with buprenorphine because the subsequent switch to
methadone doesn’t come with the mortality risk.
Sumner SA,
Mercado-Crespo MC, Spelke MB, Paulozzi L, Sugerman DE, Hillis SD, Stanley C.
Prehosp Emerg Care. 2015
Sep 18:1-6. [Epub ahead of print]
Comment: Really
interesting analysis of medical examiner records. They looked at opioid
overdose decedents who had undergone resuscitation efforts and then looked to
see if they had received naloxone during those paramedic efforts. Naloxone was
given in two-thirds of cases and was much more likely to be given to younger
men with evidence of illicit drug use. Should paramedics be more willing to use
naloxone in settings that don’t look like a “classic heroin overdose”? Or would
that have negative effects? This is a really interesting topic for emergency
medicine.
Winston I, McDonald R,
Tas B, Strang J.
BMJ Case Rep. 2015 Sep
14;2015. pii: bcr2015210391. doi: 10.1136/bcr-2015-210391.
Comment: I
can’t access this but the abstract purports that it is the “first-ever account”
of a lay person titrating naloxone to respiratory function. Not to be snooty, but that’s
really old news.
Fischer B, Murphy Y,
Rudzinski K, MacPherson D.
Int J Drug Policy. 2015 Aug 14. pii:
S0955-3959(15)00242-X. doi: 10.1016/j.drugpo.2015.08.007. [Epub ahead of print]
Comment: Canada’s
conflicted drug policy.
Michel L, Lions C,
Maradan G, Mora M, Marcellin F, Morel A, Spire B, Roux P, Carrieri PM;
Methaville Study Group.
Compr Psychiatry. 2015
Oct;62:123-31. doi: 10.1016/j.comppsych.2015.07.004. Epub 2015 Jul 14.
Comment: Methadone
patients with HCV are at *way* higher risk for suicide. Increasingly, studies
suggest that there are real mental health costs to HCV and corresponding
benefits to HCV treatment.
Fulton-Kehoe D, Sullivan
MD, Turner JA, Garg RK, Bauer AM, Wickizer TM, Franklin GM.
Med Care. 2015
Aug;53(8):679-85. doi: 10.1097/MLR.0000000000000384.
Comment: The
increasing risk of overdose with opioid dose is likely about linear and just
knowing dose or dosing frequency/duration doesn’t tell you the whole picture.
Unfortunately big data just doesn’t answer the deep questions about substance use.
Ahmad SA, Scolnik D,
Snehal V, Glatstein M.
Am J Ther. 2015
Jan-Feb;22(1):e14-6. doi: 10.1097/MJT.0b013e318293b0e8. Review.
Comment: I
can’t access the full article, but am not surprised that naloxone doesn’t
reverse clonidine toxicity.
ReplyDeleteWhen you go into any drug and alcohol rehab center, you will find that it is full of people who are just like you - people with addiction problems who have been unable to tackle them on their own.[www.aacsatlanta.com] see moredrug alcohol evaluation